NCT03729245
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- NCT03729245 ↗
- Terminated
- Nektar Therapeutics
- Focused
We haven't built an HCP commentary report on NCT03729245 (bempegaldesleukin, sunitinib and 2 more in Renal Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03729245 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
- Interventions
- bempegaldesleukin; sunitinib; nivolumab; cabozantinib
- Arms
- Combination of bempegaldesleukin + nivolumab · Experimental
- sunitinib or cabozantinib · Active comparator
- Enrollment
- 623
- Primary outcomes
- Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC
- Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC
- Sponsor
- Nektar Therapeutics with Bristol-Myers Squibb
- Start
- Dec 18, 2018
- Primary completion
- Jan 7, 2022
- Results posted
- Yes
- Registry record
- NCT03729245 · updated Apr 11, 2023
Publications
linked from the registry- Tannir NM, Formiga MN, Penkov K, Kislov N, Vasiliev A, Gunnar Skare N, Hong W, Dai S, Tang L, Qureshi A, Zalevsky J, Tagliaferri MA, George D, Agarwal N, Pal S. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09). J Clin Oncol. 2024 Aug 10;42(23):2800-2811. doi: 10.1200/JCO.23.02082. Epub 2024 Jun 5. PubMed 38838287